NMN capsule vs sublingual absorption
One small human trial compared NMN capsules with sublingual tablets. Here is what it measured, what it did not, and how to choose a routine.
By the Knurle editorial team · How we source this
Sublingual NMN raised its terminal metabolites faster than the oral route in the only human trial to compare them directly. Blood levels of NMN itself, nicotinamide and NAD⁺ showed no significant difference between routes over the first hour of measurement.
That trial was a single dose in 14 healthy adult men, with blood drawn for 60 minutes, so it describes the first hour rather than the long run, and both routes were tolerated without reported adverse events a 2026 crossover study in Scientific Reports. Good news, quietly delivered.
Is sublingual NMN better absorbed than a capsule?
On the measure the researchers picked, yes, and briefly. In a randomized, two-period crossover trial, 14 healthy adult men took NMN by mouth and under the tongue, separated by an 8-day washout, and the incremental area under the curve was significantly higher for the terminal catabolites 2PY and 4PY after the sublingual dose the same 2026 crossover study.
On the measures people usually mean by absorption, the routes looked alike. Blood concentrations of NMN, nicotinamide and NAD⁺ did not differ significantly between oral and sublingual administration across the 60 minutes of sampling Scientific Reports, 2026.
Terminal catabolites sit at the end of the metabolic line. They are not NMN arriving intact somewhere useful, which is worth holding in mind before you rewrite your morning.
What the NMN capsule vs sublingual study measured
Fourteen men is a small group, and an hour is a short window. The authors say the metabolic origin of the 2PY and 4PY increase could not be distinguished, so the data cannot tell you whether more NMN reached tissue or whether the route changed the pace of breakdown the 2026 crossover trial.
The hypothesis under test is worth knowing. Sublingual dosing is proposed to bypass hepatic first-pass metabolism, the liver processing a swallowed dose before it circulates Scientific Reports, 2026. A faster appearance of terminal metabolites fits a different early handling. That is as far as the paper goes.
Does sublingual NMN bypass first-pass metabolism?
Not established. A 2026 review of NAD⁺ biology and supplementation describes NAD⁺ responses as nonlinear, shaped by dose, age, metabolic state and route of administration, with feedback mechanisms and saturation in the system a 2026 review in Molecular Biology Reports. A route that moves a metabolite faster in the first hour is not automatically a route that leaves more NAD⁺ in tissue.
The same review notes that oral NAD⁺ precursors such as nicotinamide riboside and NMN can raise circulating NAD⁺, while clinical benefits remain variable and context-dependent Molecular Biology Reports, 2026.
How much NMN do the studies use?
Oral NMN has been given as single doses of 100, 250 and 500 mg, and as daily doses of 300, 600 and 900 mg for 60 days, while the sublingual comparison used one dose by each route, as reported in a 2020 clinical trial in Endocrine Journal, a 2023 randomized trial in GeroScience and the 2026 crossover study.
| Route | Amounts used in the research | What changed | Practical note |
|---|---|---|---|
| Oral capsule or powder | 100, 250 and 500 mg single doses; 300, 600 and 900 mg daily for 60 days | Blood NAD⁺ rose in every treated group, highest at 600 and 900 mg | Well tolerated up to 900 mg daily over 60 days |
| Sublingual | One dose, compared with the same men taking it orally | Faster early rise in 2PY and 4PY; no significant difference in NMN, NAM or NAD⁺ | One acute study, no longer-term data |
In the 60-day trial of 80 middle-aged adults, blood NAD⁺ was significantly higher than placebo in all three treated groups at day 30 and day 60, and walking distance in a six-minute test improved in the treated groups GeroScience, 2023. The authors report no safety issues and describe oral NMN as well tolerated up to 900 mg daily the same trial.
Earlier, a single oral dose of 100, 250 or 500 mg in 10 healthy men produced no significant clinical symptoms and no meaningful changes in heart rate, blood pressure, oxygen saturation or body temperature Endocrine Journal, 2020.
Should I take NMN in a capsule or under my tongue?
A capsule is the better-studied shape. The longer human trials, running from 14 days to 12 weeks, all used oral dosing a 2024 meta-analysis in Current Diabetes Reports. The sublingual side of the ledger is one crossover study that followed people for an hour Scientific Reports, 2026. If you want the route with a track record, swallow the capsule.
What the trials do not show is a consistent change in metabolic outcomes. That 2024 systematic review and meta-analysis pooled eight randomized controlled trials of NMN, 342 mostly middle-aged and older adults, doses of 250 to 2000 mg a day for 14 days to 12 weeks, and found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile Current Diabetes Reports, 2024. Blood NAD⁺ goes up; the downstream scoreboard is still being argued about.
Sublingual dosing is not wrong, it is early. There is no published human data here on emptying a capsule under your tongue, and the crossover study used a prepared sublingual dose, so those results do not travel automatically to a home experiment.
A simple routine
Pick a route, pick a time you will actually remember, and keep it steady. Most people land on the morning with breakfast or the evening next to the toothbrush. A daily dose that fits your bathroom shelf beats a cleverer dose you skip.
We make Spark, 500 mg of NMN at 99.9% purity in one vegan capsule a day, which sits inside the range the 60-day trial covered GeroScience, 2023. If you are weighing precursors or wondering why 500 mg, our piece on NMN vs NR and what dose and purity means walks through it. If you are the sort who plans months ahead, can you take berberine long term shows how the same questions get asked about another daily ingredient, which is a useful rehearsal before you commit shelf space.
FAQ
Is sublingual NMN better absorbed than a capsule? On the only direct human comparison, sublingual NMN produced a larger early rise in the terminal metabolites 2PY and 4PY, while blood NMN, nicotinamide and NAD⁺ did not differ significantly between the two routes Scientific Reports, 2026.
How long does NMN take to raise NAD⁺? In a 60-day trial of daily oral dosing, blood NAD⁺ was significantly higher than placebo at day 30 and at day 60 GeroScience, 2023. Acute studies measure the first hour, so they cannot answer this one.
How much NMN should I take? Daily doses of 300, 600 and 900 mg all raised blood NAD⁺ over 60 days, with the highest concentrations at 600 and 900 mg, and 900 mg was well tolerated GeroScience, 2023. Single oral doses from 100 to 500 mg raised no safety signals in an earlier trial of 10 men Endocrine Journal, 2020.
Is sublingual NMN safe? In the crossover trial both routes were well tolerated, with no adverse events reported during the 60-minute observation Scientific Reports, 2026. The longer safety record comes from oral dosing over 60 days.
Can I take NMN every day? Daily oral dosing for 60 days was well tolerated in 80 adults GeroScience, 2023. The 2026 review notes that longer and better-designed clinical studies are still needed to define effective and safe long-term use Molecular Biology Reports, 2026.
Sources
- Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men, Scientific reports, 2026 (Journal Article, Randomized Controlled Trial, Comparative Study, Research Support, Non-U.S. Gov't)
- Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men, Endocrine journal, 2020 (Clinical Trial, Journal Article)
- NAD⁺ biology and supplementation: From mechanisms to clinical perspectives, Molecular biology reports, 2026 (Journal Article, Review)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial, GeroScience, 2023 (Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't)
- Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials, Current diabetes reports, 2024 (Journal Article, Meta-Analysis, Systematic Review)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.






